Posted by Michael Wonder on 20 Dec 2022
HUTCHMED initiates rolling submission of NDA to US FDA for fruquintinib for the treatment of refractory colorectal cancer
19 December 2022 - Company plans to complete rolling submission to the US in the first half of 2023, followed by filings in Europe and Japan.
HUTCHMED today announces that it has initiated the filing of a rolling submission of a new drug application to the US FDA for fruquintinib, a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, for the treatment of refractory metastatic colorectal cancer.
